

Index

- ABCE models 18
 Abuja Goals Fund *see* AGF
 AD (auto-disposable syringes) 81, 83
 transmission probability 83
 Addis Ababa conference *see* Civil Society Panel
 Addis Ababa Youth Forum Prioritization 347
 adolescent sexual activity 239, 241, 245, 251–2, 254, 258,
 260–1, 269–70, *see also* keeping girls in school
 Afrobarometer project 227, 230–1, 232
 age factors 20–1
 AGF (Abuja Goals Fund) 6, 183, 184, 186, 201–5, 206,
 222, 229–33, 344, 346, 347
 AIDS
 deaths averted costs 306–7
 denial by politicians 234, 235
 epidemiology 301
 funding 342
 future scenarios 304–5
 R&D *see* vaccine research and development
 retro-virus discovered 61, *see also* ART
 trials 314–18
 vaccine 7
AIDS in the Twenty-First Century: Disease and
 Globalisation 68
AIDS: Taking a Long-Term View 2
 AIDS vaccine
 accelerating development 309–12, 346, 347
 access to 325
 alternatives to 326
 benefit-cost ratios 310, 321, 326
 benefits 309
 costs 305–6, 321, 322–3
 in sub-Saharan Africa 306
 disinhibition 146, 324–5
 effectiveness 323–4
 and epidemic future 324
 paying for 325–6
 research 330
 societal benefits 321
 synergistic benefits 325
 aids2031 Consortium xx, 2
 Modeling Working Group xix
 AIDSCost projection program 128, 147
 AIM (AIDS Impact Model) 78–9, 89–90, 96–7
 alcohol
 abuse as HIV epidemic driver 285
 Laffer Curve 244
 problematic use of 239, 242–5
 substitution 244
 taxation 241, 243, 247, 250–1, 254, 257, 261, 262–3,
 267, 268, 269–70, 293, 295–6, 346, 347, 348
 Angola
 alcohol tax 262–3
 blood supply testing 86
 HIV epidemic scale 65–6
 HIV incidence/prevalence 13
 key indicators 115–16
 anthropometric outcomes 55
 Appel, Jacob 191
 ART (anti-retroviral treatment)
 access to treatment 125, 140–1, 181, 185, 233–4
 AIDSCost projection program 128, 147
 anti-retroviral prophylaxis options 109–10, 122
 at-risk groups targeting strategy 312
 and behavioral responses 50–1
 benefit-cost analyses
 for successful infection prevention treatment 159–60
 for unsuccessful infection prevention treatment 156
 benefit-cost ratios 76, 77–8, 137, 138–9, 143, 145,
 178–82
 benefit-cost results 141–2, 146–8
 best treatment stage 125–6
 CD4 cells 110–12, 125–6, 127–30, 136, 137–9, 141–2,
 143–4, 156, 160, 178
 CD4 counts and eligibility 181
 cost-effectiveness 141–2
 costs 32, 77, 126–7, 145, 169, 178
 coverage 128
 and family planning 222
 drug costs 308
 and dynamics of HIV infection 103–4
 eligibility guidelines 213–14
 extension of 15
 feedback effects 219–20
 future cost per patient 178–9
 historical counterfactual 135
 HIV transmission models 79–81, 131–3
 incremental spending 140
 infections reduction incremental benefits 194
 life years gained 179–81, 184
 lifelong treatment 109–10, 112
 mother-to-child infections 75

- national uptake rate 128
- Nobel Laureate Economist Expert Panel findings on 339
- non-AIDS mortality rate 180
- numbers treated by 1
- oral 301
- patient life expectancy 138–9
- and prevention techniques 70
- primary infection prevention 159
- scaling-up benefits 181, 346, 347
- scaling-up enrollment 343, 347–8
- secondary infection prevention 159
- simulated scenarios 135–7
- spillover benefits 145
- statistics provision 79
- in sub-Saharan Africa xix
- sufficient damage factor 127
- survival years 180–1
- TDF/FTC combination 54
- test-and-treat strategy 12–14, 18, 19–20, 22–3, 25, 53–4, 58, 112, 192
- topical 301
- topical microbicides 238
- treatment cost per person/year 135, 173–4
- treatment criteria 128
- treatment dynamics modeling 127–30
- treatment eligibility 334
- treatment emergence 125
- treatment impact modeling 130–3, 142–5
- treatment unit costs 133–5
- treatment uptake rate modeling 128–30
 - impact of 135
- uptake projection 139–40
- value of lives saved 78
- zero uptake 135, 136
 - and benefit-cost ratios 151
 - simulation results 139
- ARV (anti-retroviral prophylaxis regimen) 109–10, 135, 160–3, 172–3, 175–6
 - adverse side effects 174
 - and AIDS vaccine 305
 - benefit-cost ratio 173
 - cost decline 179
 - deployment of 146
 - potential cost reduction 179
- Aryeetey, Ernest 337–8
- at-risk groups targeting strategy 312
- AVERT model 79–81
- AZT (Zidovudine) program 162

- B/C ratios, naive estimates of 155
- Baltussen, Rob 5
- Banerjee, Abhijit 191
- Barnett, Tony 6
- Bärnighausen, Till 6
- BCC (behavioral change communication) 16
- BCR *see* benefit-cost ratios
- behavioral prevention programs 14–15

- Behrman, Jere 4, 349
- benefit estimates 103–4
- benefit-cost analyses 21, 23
 - continued investment 308–9
 - DALYs (disability-adjusted life years) 20, 22, 26–9, 32–3, 34–40, 41–2, 49, 62, 226
 - decline in World Bank 190
 - dynamic framework time representation 155–60
 - HC (Human Capital) approach 170
 - HIV treatment pre-pregnancy 164–6
 - information campaigns (IC) 25–6
 - and interventions 108
 - life-cycle perspective 26, 30, 62
 - Nobel Laureate Economist Expert Panel findings on 337
 - for policy interventions 26–32
 - discounting 31
 - estimation challenges 31–2
 - general considerations 26–30
 - interaction among solutions 31
 - prices 30
 - range of costs 31
 - range of impacts 30
 - scale 31
 - pregnant women 167–8
 - and sets of objects 283
 - for successful infection prevention treatment 159–60
 - and unrecognized metaphors 281
 - for unsuccessful infection prevention treatment 156
 - vaccine research and development 304–9
 - WTP (willingness to pay) 170–1
- benefit-cost ratios 5, 36–7, 40–1, 181–2, 189
 - AIDS vaccine development 310
 - ART 32, 76, 77–8, 137, 138–9, 143, 145, 146–8, 178–82
 - and ARV provision 173
 - CCTs 220–2
 - CD4 cell count 158–60
 - community health 198
 - cross-country variations 293
 - discounted/undiscounted 156, 175
 - health system strengthening 208
 - HIV reduction interventions 34–7, 41–2, 63–4, 174, 293
 - infections averted 32
 - interventions 260–3
 - male circumcision 36–7, 40–1, 63–4, 339
 - pMTCT in sub-Saharan Africa 160–1, 163, 174–5
 - procedures summary 32–3
 - treatment costs 32
 - treatment as prevention 151
 - unit costs 294–5
 - varying average costs 294–5
 - VSL (Value of a Statistical Life) approach 170–1
- Benin
 - alcohol tax 262–3
 - blood supply testing 86
 - HIV incidence/prevalence 13, 114–17
 - key indicators 115–16
 - problems faced by government (Afrobarometer) 232

352 Index

- blockbuster drugs 303
blood safety intervention 186
blood transfusions 4, 74, 86–8, 89, 102–3, 346, 347
Bloom, David 5–6
BMGF (Bill and Melinda Gates Foundation) 213
body undergoing treatment metaphor 283–4
Bollinger, Lori 4, 102, 105, 121, 169–70, 171, 259, 347–8
Botswana
 alcohol tax 262–3
 health priority survey 230–1
 HIV epidemic scale 65–6
 HIV incidence/prevalence 12, 13, 29, 30, 34, 39–40
 key indicators 115–16
 life expectancy with/without AIDS 162
 male circumcision 25, 40–1
 problems faced by government (Afrobarometer) 232
 resources allocated to 15–17
 unmet need for family planning 165
Brandeau, M. L. 295
Brazil, AIDS vaccine 325
Brent, Robert 5
British Columbia Center for Excellence on HIV/AIDS 69–70
Burkina Faso
 Abuja target 202
 alcohol tax 262–3
 HIV incidence/prevalence 13, 114–17
 key indicators 115–16
 life expectancy with/without AIDS 162
 unmet need for family planning 165
Burundi
 alcohol tax 262–3
 HIV incidence/prevalence 13
 key indicators 115–16
 life expectancy with/without AIDS 162
 unmet need for family planning 165
bush circumcisions 52

Cambodia, conditional cash transfers 254
Cameroon
 alcohol tax 262–3
 HIV incidence/prevalence 13
 key indicators 115–16
 life expectancy with/without AIDS 162
 unmet need for family planning 165
Campbell Collaboration 65
cancer as investment priority 189
canine distemper, and vaccine research and development 313
Cape Verde, problems faced by government (Afrobarometer) 232
CAPRISA (Centre for the AIDS Programme of Research in South Africa) 64
CAPRISA Study 54
cash incentive programs *see* CCT
CBA (cost-benefit analysis) *see* benefit-cost analyses
CCT (conditional cash transfer) 21, 23, 31, 53, 54–8, 191–3, 218
 benefit-cost ratios 220–2
 conceptual foundations of 56
 current evidence on 57–8
 female education 245
 and HIV awareness 192
 and HIV testing 228–9
 and infection reduction 222
 and joint objectives 184
 keeping girls in school *see* keeping girls in school
 potential impacts of 186
 rationale for 54–7
 RESPECT study 193
CD4 cells 110–12, 125–6, 127–30, 136, 137–9, 141–2, 143–4, 156, 160, 172, 173, 178, 199
 cell count and ART eligibility 181
 cell count benefit-cost ratios 158–60
 and death probability 180–1
 point of care dipsticks 179
 screening 161
CEA *see* cost-effectiveness analyses
Central African Republic
 alcohol tax 262–3
 health worker shortage 196
 HIV incidence/prevalence 13, 196
 key indicators 115–16
 life expectancy with/without AIDS 162
Chad
 alcohol tax 262–3
 HIV incidence/prevalence 13
 key indicators 115–16
 unmet need for family planning 165
CHAHA program 248–9
childhood diseases, as investment priority 189
Chimeric Venezuelan Equine Encephalitis 313
China, conditional cash transfers (one-child policy) 191
CHWs (community health workers)
 deployment 216, 218
 Technical Task Force 186, 196, 197–9
 training costs/benefits 220–2
circumcision *see* MC
Civil Society Panel 341, 349
 Abuja Goals Fund 344
 AIDS funding 342
 ART (anti-retroviral treatment) scaled-up enrollment 343
 CCT (conditional cash transfer) and keeping girls in school 343–4
 keeping girls in school 343–4, *see also* keeping girls in school
 mother-to-child transmission prevention (pMTCT) 342–3, 347–8
 redefining priorities theme 341
CM (contingency management) 55–6
CMH (Commission on Macroeconomics and Health) 104, 195, 203
COD (cash on delivery)

- and Abuja Goals Fund (AGF) 201–5, 206, 229–33
- donor assistance 184
- to governments 218
- Collier, Paul 337–8
- combination prevention 145
- commodity approach to strategies 15
- community health workers 183, 184, 206, 207, 228
- community mobilization 248–9, 253, 255, 259, 265, 267, 268, 269–70, 293
- Community Systems Strengthening Framework 235
- Comoros
 - alcohol tax 262–3
 - HIV incidence/prevalence 13, 114–17
 - key indicators 115–16
- concurrent sexual partners, as HIV epidemic driver 285
- condoms 11, 19, 51, 56, 68, 170, 248
- Congo
 - Abuja target 202
 - alcohol tax 262–3
 - HIV incidence/prevalence 13, 114–17
 - key indicators 115–16
 - life expectancy with/without AIDS 162
 - unmet need for family planning 165
- contraception, unmet need for 164
 - see also* condoms; family planning
- Copenhagen Consensus 2–3, 7, 8, 71
- Copenhagen Consensus Center, global development project (2008) 2
- Copenhagen Consensus Challenge paper 245
- Copenhagen Consensus project (2004) 2
- cost-effectiveness xx, 11, 17–23, 37–9, 49, 58
 - blood transfusions 74, 86–8
 - ICER (incremental cost-effectiveness ratio) 75–6
 - injecting drug users 92–5
 - interventions 17–23, 242–5, 260
 - medical injections 74, 81–6
 - mother-to-child transmission 74, 121
 - in sub-Saharan Africa 11, 20, 104
- cost-effectiveness analyses 22, 283
 - and unrecognized metaphors 281
- cost estimates 103
- cost per death 194, 198
- cost per infection 104
- Cote d'Ivoire
 - alcohol tax 262–3
 - HIV incidence/prevalence 13, 114–17
 - key indicators 115–16
 - life expectancy with/without AIDS 162
 - OIs (opportunistic infections) 76–7, 78
 - unmet need for family planning 165
- cotrimoxazole prophylaxis 161
- couple-based HIV testing 20
- CRAG (cryptococcal antigen)
 - costs and benefits 186, 200–1, 208
 - testing 199–200, 201, 228
- critical enablers 188–9
- cross-intervention benefits 347
- cryptococcal meningitis (CM) 183, 200–1, 206, 216, 218, 220, 340
- Cryptococcosis neoformans 184, 199–201
- cultural practices, as HIV epidemic driver 285
- Cytomegalovirus Clinical Development Program 313
- DALYs (disability-adjusted life years) 20, 22, 26–9, 34–40, 41–2, 49, 62, 63–4, 75–6, 104, 170–1, 175–6, 189–90, 197, 200, 203, 205, 206, 207, 226, 243, 260, 263–5, 349
 - by country 271–2
 - incremental cost 274–5
 - parameters 260–1
- DCP2 190–1
- de Walque, Damien 4
- dead metaphors 282
- deaths averted 188–9, 194, 202, 203, 204, 306–7, 308
- DemProj software tool 78
- diagnostic tests 300
- discounting 171–2, 173, 175, 189–90, 200, 263, 333
- disinhibition 146, 324–5, 339
- Djibouti
 - Abuja target 202
 - key indicators 115–16
- DMPTT *see* Male Circumcision: Decision Makers' Program Planning Tool
- donor support flat-lining 213–14
- dose-response 284
- drug costs 126–7, 308
- drug development 300
- drug supply systems intervention 186
- drug users, injecting 92–5
- Duflo, Esther 191
- Earth Institute Technical Taskforce 195
- ecology of risk 285, 286
- The Economist*, end of AIDS? 12
- Efavirenz 111, 126
- effectiveness estimates 103–4
- efficiency solution 188
- embodiment of social conditions 287–8
- emergency rescue intervention 186
- epidemic model 295
- EPP (Estimation and Projection Package) 78
- Equatorial Guinea
 - alcohol tax 262–3
 - HIV incidence/prevalence 13
 - key indicators 115–16
- Eritrea
 - alcohol tax 262–3
 - HIV incidence/prevalence 13, 114–17
 - infant mortality 204
 - key indicators 115–16
 - life expectancy with/without AIDS 162
- Ethiopia
 - alcohol tax 262–3
 - HIV prevalence 12, 114–17, 296–7

354 Index

- Ethiopia (*cont.*)
 key indicators 115–16
 life expectancy with/without AIDS 162
 life insurance incentivization 296–7
 Millennium Village Project (MVP) 247
 PEPFAR-funded interventions 255
 unmet need for family planning 165
 Voices of the Poor project 196
 evidence-based allocation strategy 17–18
 external validity of interventions 294
- faith-based abstinence 68
 family planning 97, 117, 161, 163–4, 197, 198, 202, 222
 cost-effectiveness of 164, 198–9
 social benefits 164
 unmet need for in sub-Saharan Africa 165
 Farm Input Subsidy Programme 247
 FDA, and microbicide 64
 FEM-PrEP trial 54
 female education 245
 female sex workers 296–7
 FFS (Farmer Field School) 247, 252
 first-line treatment benefits/costs 157
 flat-lining donor support 213–14
 Forsythe, Stephen 7
 funding 1
 alternative use for 214–15
 competing demands 213–14
- G8 (Gleneagles 2005) 185
 Gabon
 alcohol tax 262–3
 HIV incidence/prevalence 13
 key indicators 115–16
 life expectancy with/without AIDS 162
 Gambia
 alcohol tax 262–3
 HIV incidence/prevalence 13
 key indicators 115–16
 Gardasil 322, 323, 325
 Garnett, Geoffrey 5, 173–4, 178–82, 347–8
 GAVI Alliance 184–6
 gender inequalities, as HIV epidemic driver 285
 gender role perceptions/training 239, 240, 246–7, 248–9, 252, 254–5, 258–9, 263, 267, 269–70, 293
 general structure (GS) interventions 216–18, 221
 genital lesions 285
 Georgetown University Expert Panel *see* Nobel Laureate Economist Expert Panel
 GFATM *see* Global Fund to Fight AIDS, Tuberculosis and Malaria
 Ghana
 alcohol tax 262–3
 health priority survey 230–1
 HIV incidence/prevalence 13, 114–17
 HIV/AIDS stigma 248–9
 key indicators 115–16
 problems faced by government (Afrobarometer) 232
 sexually transmitted HIV 11
 unmet need for family planning 165
 Voices of the Poor project 196
 girls in school 239, 241, 245, 251–2, 254, 258, 260–1, 267, 268, 269–70, 284, 343–4
 Gleneagles Summit (2006) 125
Global Crises, Global Solutions 184–5, 190
 Global Fund Forum 342
 Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) 61, 182, 184–6, 189, 202–3, 213, 214–15, 230, 233–6, 346
 Global Fund-hosted Event Prioritization 346
 global political commitment, to fighting HIV 213
 Global Programme on AIDS 283
 GNI per capita statistical life value 189–90
 goal-directed thinking 288
 Goals and Allocation by Cost-Effectiveness (ABCE) models 18
 Goals Model/Goals Express 79–81, 93, 96–7, 259, 265
Going Upstream: A Cost-Benefit Analysis of Social Policy Interventions to Enhance the HIV/AIDS Response in Sub-Saharan Africa 282–3
 going upstream metaphor 282–3
 Granich, Reuben M. 69–70, 191–2
 GS (general structure) interventions 216–18, 221
 Guinea
 alcohol tax 262–3
 HIV incidence/prevalence 13, 114–17
 key indicators 115–16
 Guinea-Bissau
 alcohol tax 262–3
 HIV incidence/prevalence 13
 key indicators 115–16
 life expectancy with/without AIDS 162
 Gupta, Geeta Rao 286
- Halperin, D. T. 19
 HCT *see* HTC
 health benefits, advances in estimating 190–1
 health care costs, and HIV prevention 307
 health care reform, political legitimacy of 231–3
 health center upgrade/construction intervention 186
 health inequalities and environments 287
 health priority survey 230–1
 health services strengthening, in rural areas 196–7
 health services upgrade 195–9
 health spending ratios 187
 health system capacity 226–8
 health system infrastructure and pMTCT 117–18
 health system intervention evaluation 215–17
 benefits evaluation 216–17
 costs 217
 feasibility 215
 flexibility 215
 intervention level/scope 216

- technical efficiency 215
- time lags/certainty levels 217–18
- health system strengthening 213–23, 226–36
 - access improvement 228
 - benefit evaluation 216–18
 - challenges
 - cost-benefit ratio 208
 - cost evaluation 217–18
 - feasibility 215
 - flexibility 215
 - intervention evaluation 215–16, 217
 - intervention scope 216
 - life year value monetization 226
 - methodological issues 226–33
 - Nobel Laureate Economist Expert Panel findings on 340
 - structures 214–15
- health workers
 - shortage 196
 - skills upgrade 195–9
 - staff expansion 197–9
- heart attacks, as investment priority 189
- Hecht, Robert 7
- herpes
 - as epidemic driver 285
 - and Stepping Stones 246
- heterosexual HIV transmission 303
- HIA (HIV infection averted) 63–4
- high-risk groups 153, 155
- HIPC (highly indebted poor countries) initiative 202–3
- historical counterfactual 135
- HIV
 - and alcohol consumption 242
 - in couples 126, 159
 - deaths statistics xix, 153, 299
 - dynamic models of effect on 152–5
 - epidemic drivers 285
 - epidemic scale 65–6
 - fatality rate 125
 - global political commitment to fighting 213
 - hope and social intervention 288–90
 - impact modeling 255–9
 - incidence (of infection) 131
 - incidence/prevalence ratio 146–8, 213, 226–8
 - infections averted 255–9, 271–2
 - modes of transmission 66–7
 - POC (point-of-care) diagnostic tests 119–21
 - in women in sub-Saharan Africa 172–3
 - see also* vaccine research and development
- HIV counseling, universal 183
- HIV information, universal 183
- HIV prevention, as investment priority 189
- HIV programs, demand side 218
- HIV testing
 - monetization 229
 - universal 183, 228–9
- HIV transmission
 - heterosexual 303
 - models 79–81, 131–3
 - rate estimation 151
 - in sub-Saharan Africa 238
 - susceptibility and income inequality 287
- HIV treatment
 - for all women 164–6
 - benefits of prevention 306–8
 - costs 70
 - efficiency 215
 - immediacy 70
 - individual effects 70
 - population effects 70
 - programs' integration with primary health care 214–15
 - selective expansion 214–15
 - selective integration 214–15
 - stand-alone programs 215
 - see also* ART (anti-retroviral treatment); HSS (health system strengthening)
- HIV vulnerability, social drivers 239
- HIV-infected children, survival rate 77
- HIV/AIDS
 - disease statistics 200
 - R&D *see* vaccine research and development
 - social policy interventions 281–90
 - spending and health systems strengthening 186–7
- HIVNS (HIV-focused non-structural) interventions 216–18, 221
- HLT (High Level Taskforce on International Innovative Financing for Health Systems) 185, 195, 202–3
- Hontelez, Jan 5
- hope
 - analytical advantages 289
 - as diagnostic tool 289–90
 - and income 289
 - and optimism 288
 - and palliative care 289
 - and social intervention 288–90
- HSS (health systems strengthening) 184, 186–7, 204–5
 - expansion of 214–15
 - and health worker skills upgrade 195–9
 - intervention scale 219
 - interventions implementation time 219
 - potential of 215
 - priority setting 220
 - targeting vulnerable populations 220
 - unintended consequences 218–19
- HTC (HIV testing and counseling) 14–15, 19–20, 22–3, 25, 41–2
 - benefits of 49–50, 62–3
 - and Civil Society Panel 344
 - cost-benefit ratio 63–4
 - cost-effectiveness 37
 - costs of 33–4
 - and HIV incidence 33–4
 - as prevention 69–70, 192–3
 - treatment as prevention 166–8
 - uptake at community level 248

356 Index

- Humair, Sal 6
- human resources training intervention 186
- human rights and conditional cash transfers 191
- hyperbolic discounting 190
- IAVI (International AIDS Vaccine Initiative) 299, 305–6
research developments source 313
- IC (information campaigns) 20, 25–6, 34, 41–2, 49–50,
52–3, 62, 63–4, 70–1
- ICASA 341, 346
- ICD (infectious and communicable diseases) 188
- ICER (incremental cost-effectiveness ratio) 75–6
- IDU (injecting drug use) interventions 92–5, 96, 102–3,
104, 105
- IeDEA Consortium 180
- IHP+ (International Health Partnerships) 184–5, 195,
202–3, 204–5
- IMAGE (Intervention with Microfinance for AIDS and
Gender Equity) 21, 246, 247, 252, 254–5, 258–9
- immunodeficiency virus 20–1
- impact evaluations 50
- inappropriate metaphors 281–8
- income inequality and poverty/transmission susceptibility
287
- incremental benefits 194
- incremental spending results 140
- India, conditional cash transfers (vasectomy grants) 191
- individual behavior
environment as regulator of 286–7
and risk environments 286
- infant HIV exposure diagnosis 161
- infant infections 188, 198
- infant lives saved 207
- infant mortality 203, 204
- infants, as most valued lives 190
- infection probability model 79–81
- information technology intervention 186
- initiation schools 52
- injecting drug users 75, 92–5
- Institute for Health Metrics and Evaluation 332
- intergenerational sexual behavior as HIV epidemic driver
285
- intergenerational transmission of disease 33, 285
- International Conference on AIDS (ICASA) 341, 346
- International Group on Analysis of Trends in HIV
Prevalence and Behaviors in Young People in
Countries most Affected by HIV (2010) 19
- International HIV/AIDS Alliance 248–9
- interventions
adolescent sexual activity 239, 241, 245, 247, *see also*
keeping girls in school
AGF (Abuja Goals Fund) *see* AGF
alcohol
problematic use of 239, 242–5
taxation *see* alcohol taxation
anthropometric outcomes 55
beneficiaries of 105
benefit-cost ratios 260–3
and CBA (cost-benefit analysis) 108, 242–5
CCT (conditional cash transfer) *see* CCT (conditional
cash transfer)
community mobilization *see* community mobilization
cost-effectiveness 17–23, 242–5, 260
criteria for 61–2
cross-intervention benefits 347
demand-side 55, 245
effectiveness 17–23, 242–5
evidence-based allocation strategy 17–18
external validity of 294
gender role perceptions/training *see* gender roles
perception/training
GS (general structure) 216–18
HIV infection reduction 34–9, 255–9
HIV reduction benefit-cost ratios 34–7, 41–2, 63–4,
174
HIV treatment issues 70
and HIV vulnerability social drivers 239
HIVNS (HIV-focused non-structural) 216–18, 221
and hope 288–90
HSS (health systems strengthening)
and cost-benefit analyses 221
objectives 186
scale 219
IDU 92–5
IMAGE *see* IMAGE
impact evaluations 50
implementation time 219
investment priorities 189
keeping girls in school *see* keeping girls in school
local diagnosis 289
location-specific 15–17
long-lasting 222
and MSM 53
Nobel Laureate Economist Expert Panel findings 337–8
and orphan care costs 311
pMTCT (mother-to-child transmission) 109–13, 118,
121, 151, 160–6
and population size 17
potential behavioral responses 50–2
potential beneficiaries 39–41
pre-exposure chemoprophylaxis 53, 54
preventative vs treatment 104–5
prevention efficiency 52–3
priority setting 220
sexually transmitted infections 50
Stepping Stones 246, 258–9
stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242,
255, 265
structural interventions 286
target populations 220, 247, 248–9
targeted approaches 53
and technologies/strategies 329
total costs per country 272–3
transferable social policy 283–4

- treatment for prevention (test-and-treat) 12–14, 18, 19–20, 22–3, 25, 53–4, 166–8
- trusted interventions 19
- unit costs per country 272–3
- vulnerable populations 220
- investment approach to strategies 15, 17, 21
 - six program components 15
- iPrEx study 54
- IPV (intimate partner violence) 265
- irresponsible sexual behavior as HIV epidemic driver 285

- Jamison, Dean 7, 189
- Johri, Mira 5

- Karlan, Dean 191
- Kazianga, Harounan 6–7
- keeping girls in school 245, 251–2, 254, 258, 260–1, 267, 268, 269–70, 284, 293, 294, 343–4, 346, 347
- Kemron 51
- Kenya
 - alcohol tax 262–3
 - alcohol taxation 244
 - ART cures 51
 - development indicators 227
 - family planning unmet needs 165
 - health priority survey 230–1
 - HIV epidemic scale 65–6
 - HIV incidence/prevalence 12, 13, 66–7, 296–7
 - IDU (injecting drug use) interventions 92–5, 96–7
 - key indicators 115–16
 - life expectancy with/without AIDS 162
 - life insurance incentivization 296–7
 - male circumcision 23–5
 - Millennium Village Project (MVP) 247
 - needle-sharing infections 74
 - problems faced by government (Afrobarometer) 232
 - sexually transmitted HIV 11
 - unsafe medical injections 74
- Killingo, Bactrin 341, 342, 343
- Kilonzo, Nduku 341, 342–4, 345
- Kohler, Hans-Peter 4, 349

- labor ward screening 118–19
- laboratory infrastructure improvement intervention 186
- lack of knowledge as HIV epidemic driver 285
- Laniyan, Christiana 341, 342, 343, 344
- Lesotho
 - alcohol tax 262–3
 - blood transfusion infections 74
 - bush circumcisions 52
 - health worker shortage 196
 - HIV epidemic scale 65–6
 - HIV incidence/prevalence 12, 13, 29, 30, 34, 66–7, 196
 - key indicators 115–16
 - life expectancy with/without AIDS 162
 - needle-sharing infections 74
 - problems faced by government (Afrobarometer) 232
- sexually transmitted HIV 11
- unmet need for family planning 165
- liability and cost ratio 323
- Liberia
 - Abuja target 202
 - alcohol tax 262–3
 - HIV incidence/prevalence 13
 - key indicators 115–16
 - life expectancy with/without AIDS 162
- life expectancy 161, 169
- life insurance 6–7
 - incentivization 296–7
- life-cycle perspective 26, 30, 62
- life-year costs 145
- life-year values 137, 164, 170–1, 188–9
- monetization 226
- life-years gained 179–81, 188, 200, 307
- LiST software tool 78
- location-specific interventions 15–17
- LoveLife campaign 70

- McGreevey, William 5–6
- Madagascar
 - alcohol tax 262–3
 - health priority survey 230–1
 - HIV incidence/prevalence 13
 - key indicators 115–16
 - problems faced by government (Afrobarometer) 232
- Makhwapheni Campaign* 70–1
- Making Services Work for Poor People* 233
- malaria, as investment priority 189
- Malawi
 - alcohol tax 262–3
 - cash incentive programs 21, 57–8
 - CCTs (conditional cash transfers) 192–3, 245
 - keeping girls in school 245, 254, 258
 - development indicators 227
 - donor money corruption 231
 - family planning 197
 - Farm Input Subsidy Programme 247
 - GNI per capita 226–8
 - health priority survey 230–1
 - health workers 196, 228
 - HIV epidemic scale 65–6
 - HIV incidence/prevalence 13, 34, 196
 - HIV and sexual contact 14
 - key indicators 115–16
 - life expectancy 226–8
 - with/without AIDS 162
 - male circumcision 23–5
 - Millennium Village Project (MVP) 247
 - PBI (performance-based incentive) 192
 - problems faced by government (Afrobarometer) 232
 - SIHR (Schooling, Income, and HIV Risk) study 193
 - unmet need for family planning 165
 - Voices of the Poor* project 196
- male circumcision *see* MC

358 Index

- Mali
 alcohol tax 262–3
 HIV incidence/prevalence 13, 114–17
 key indicators 115–16
 problems faced by government (Afrobarometer) 232
 mass media IC (information campaigns) 25–6, 34, 41–2, 49–50, 52–3, 62, 63, 70–1
 maternal health and child survival 111
 maternal mortality 197, 198, 202
 Mauritania
 HIV incidence/prevalence 13, 114–17
 key indicators 115–16
 Mauritius
 alcohol tax 262–3
 HIV incidence/prevalence 13, 114–17
 IDU (injecting drug use) infection 92–5
 key indicators 115–16
 MBB (marginal budgeting for bottlenecks) 185, 203
 Mbeki, President Thabo 234, 235
 MC (male circumcision) 4, 12, 15, 18, 21, 22–5, 41–2, 49–50, 300, 301, 346
 benefit-cost ratios 36–7, 40–1, 63–4, 339
 bush circumcisions 52
 cost-effectiveness of 58, 62
 costs of 33
 as high priority 348
 infant 339, 348
 and infection prevention 326
 intervention efficiency 52–3
 intervention requirements 39–41
 key issues 69
 lack of as HIV epidemic driver 285
 long-term benefits 25–6, 62, 66, 68–9
 Male Circumcision: Decision Makers' Program Planning
 Tool (DMPPT) 18
 neonatal 25, 52
 uptake and resources 323
 MDGs *see* Millennium Development Goals
 Medecins Sans Frontiers 159
 medical injections 4, 74, 81–5, 86, 102–3
 medical male circumcision *see* MC
 Mema wa Vijana intervention 255
 men who have sex with men *see* MSM
 Menberu, Retta 341, 343, 345
 Merck vaccine failure 302
 metaphorical language in social policy interventions 281–90
 metaphors
 and cost-effective analyses 281
 inappropriate 281–8
 risk behavior 284–6
 structural drivers 284–6
 unexamined 281–6
 unrecognized 281
 Mexico, conditional cash transfers 191, 254
 microbicides and HIV risk 64, 71
 microfinance schemes 21, 246, 247
 Millennium Development Goals
 failure to achieve 341
 Goal 4 (reduce child mortality) 121–2
 Goal 5 (improve maternal health) 121–2
 Goal 6 (combat HIV/AIDS) 121–2, 242
 Millennium Village Project (MVP) 247, 252
 Mills, Anne 185
 Mix Market platform 252
 modes of transmission 66–7
 Montaner, J. S. G. 69–70
 moral hazard 146
More than good intentions 191
 most-valued persons 189–90
 MOT (Modes of Transmission) model 81, 102, 103–4
 mother-to-child transmission 4, 5, 74, 75, 77, 88–92, 160–6
 anti-retroviral prophylaxis options 109–10, 121
 AP (assessment paper) analysis 107, 108, 110–12
 CBA (cost-benefit analysis) 108
 CD4 screening 161
 contraception 164
 family planning 117, 161, 163–4
 cost-effectiveness of 164
 infant HIV exposure diagnosis 161
 labor ward screening 118–19
 maternal health and child survival 111
 maternal mortality 197
 multiplex POC (point-of-care) diagnostic tests 119–21
 non-health facility births 119
 pMTCT cascade 107, 117, 118, 122
 potential HIV rates in sub-Saharan Africa 163
 prevention (pMTCT) 77, 78, 79, 91–2, 97, 103, 105, 107, 108, 169–70, 347–8
 analytic timeframe 111–12
 benefit-cost reduction 174–5, 342–3
 CD4 cell count 110–12, 172
 and Civil Society Panel 342–3
 comprehensive vs narrow approach to 108–9
 costs
 and health system infrastructure 113
 and HIV prevalence 113
 emerging technology 122
 forward transmission impact 107, 112
 full benefits definition 161
 and health system infrastructure 117–18
 intervention options 109–12, 113, 151
 key challenges 113–18
 Nobel Laureate Economist Expert Panel findings 342–3
 pre-pregnancy 164–6
 scaling up 346, 347
 services increase requirements 121–2
 solutions 118–21
 therapeutic options 111, 112, 121
 treatment evaluation 172
 treatment targets 156
 treatment vs family planning 163–4
 primary prevention 164

- screening tests 161
 in sub-Saharan Africa 74, 107, 163
 testing and counseling 161
 treatment for prevention (test-and-treat) 12–14, 18,
 19–20, 22–3, 25, 53–4, 166–8
 WHO Option A strategies 107–8
- Mozambique
 alcohol tax 262–3
 development indicators 227
 health worker shortage 196
 HIV epidemic scale 65–6
 HIV incidence/prevalence 13, 34, 39–40, 196
 key indicators 115–16
 life expectancy with/without AIDS 162
 male circumcision 40–1
 problems faced by government (Afrobarometer) 232
 unmet need for family planning 165
- MSM (men who have sex with men) 4, 53, 66–7, 69, 238
- MTCT *see* mother-to-child transmission
- multiple partners 126, 159
- multiplex POC (point-of-care) diagnostic tests 119–21
- Namibia
 alcohol tax 262–3
 health priority survey 230–1
 HIV incidence/prevalence 13, 34
 key indicators 115–16
 life expectancy with/without AIDS 162
 male circumcision 23–5
 problems faced by government (Afrobarometer) 232
 unmet need for family planning 165
- NAT (nucleic acid amplification testing) 86
- national epidemics 283
- national strategies xx
- National Technical Teams (NTTs) 345
- Natrass, Nicoli 6
- needle-exchange 105
- neonatal circumcision 25, 52
- Nevaprine 126, 161–2
- Niger
 alcohol tax 262–3
 blood supply testing 86
 HIV incidence/prevalence 13, 114–17
 key indicators 115–16
- Nigeria
 alcohol tax 262–3
 development indicators 227
 health system capacity 226–8
 HIV epidemic scale 65–6
 HIV incidence/prevalence 13
 key indicators 115–16
 life expectancy with/without AIDS 162
 problems faced by government (Afrobarometer) 232
 unmet need for family planning 165
- Nobel Laureate Economist Expert Panel 337–8
- non-sexual HIV transmission prevention
 AIDS impact model 78–9
 analysis methods 102, 103–4
 benefits calculation 76–8
 benefits summary 96
 blood transfusions 74, 86–8, 102–3
 Goals Model/Goals Express 79–81
 HIV infections averted model 78
 injecting drug users 92–5
 medical injections 4, 74, 81–5, 86, 102–3
 mother-to-child transmission 4, 5, 74, 88–92, 169–70
 multi-country analysis options/limitations 102–3
 recommendations 96–7
 resource allocation equity 105
 NVP (Nevirapine) program 126, 161–2
- O&G model of infections 152–3
 and high-risk groups 155
 infection flows 155
 with interventions 153–4
 transmission mechanism specification 154–5
- Odumbe, Ken 341, 342, 345
- OIs (opportunistic infections) 76–7, 78, 89, 307, 311
- One Million Community Health Workers* 195
- operations research intervention 186
- opiate substitute therapies 105
- oppression illness 287
- oral anti-retrovirals 301
- oral prophylaxis 238
- orphan care costs 311
- OST (opioid substitution therapy) 75, 105
- Over, Mead 5, 173–4, 178–82, 347–8
- Padian, N. S. 2
- patient transport intervention 186
- PBI (performance-based incentive) 192
- Pearl Omega 51
- Peer Group IC (information campaigns) 25–6, 34, 41–2,
 49–50, 52–3, 62, 63
- PEPFAR (Presidential Emergency Plan for AIDS Relief)
 61, 67, 92–5, 179, 182, 184–6, 189, 213, 214–15,
 217, 255
- pilot studies, external validity of 294
- Piot, Peter xx
- Platform for Health System Strengthening 195
- pMTCT *see* mother-to-child transmission
- POC (point-of-care) diagnostic tests 119–21
- Poor Economics, a Radical Rethinking of the Way to Fight
 Global Poverty* 191
- poverty as HIV epidemic driver 285, 287
- pre-exposure prophylaxis 154, 301
 chemoprophylaxis 53, 54, 58
- Prescott, Edward C. 337–8
- preventative interventions 104–5
- Prevention of Non-sexual Transmission Assessment Paper
 169–70
- primary health care, HIV treatment integration with 214–15
- primary infection prevention 159
- production function model 295

360 Index

- program enablers 194–5
 promiscuous sexual behavior as HIV epidemic driver 285
 Protocol G 313
- QALYs (quality-adjusted life years) 21–2, 75, 175–6, 349
- RAPID software tool 78
 Rasmussen, Prime Minister Anders Fogh 2
 RBF (results-based financing) 184
 RBF (results-based funding) programs 202–3
 RCTs (randomized controlled trials) 18–19, 24, 69
 hope and intervention studies 289
 role of 64–5
 and spillover benefits 145–6
 Remme, Michelle 6
 research intervention 186
 RESPECT study 57, 193
RethinkHIV project 11, 21–2, 23, 25–6, 41, 52, 61–2, 65, 74, 76, 77, 104, 108–9, 121–2, 137, 151, 155, 163, 164, 170–1, 174, 175–6, 218, 233, 238, 299, 300, 328, 342
 risk behavior 284–6
 risk compensation 146
 risk ecology 285, 286
 risk environments 285
 and individual behavior 286
 risk-taking behavior patterns 130–1, 133, 146
 risk-taking behavior research 56
 RNM (Resource Needs Model) 18
 Rome International AIDS Conference 238
 RP (revealed preference) approach 170
 Rush Foundation 2, 7, 8
 Rwanda
 Abuja target 202
 alcohol tax 262–3
 HIV awareness 192
 HIV incidence/prevalence 13
 key indicators 115–16
 life expectancy with/without AIDS 162
 life insurance incentivization 296–7
 male circumcision 23–5, 325
 OIs (opportunistic infections) 76–7, 78
 unmet need for family planning 165
- S-I (susceptible-infection) transmission system 152–5
 safe blood transfusions *see* blood transfusions
 safe medical injections 81–6
 precautions intervention 186
 Salomon, Joshua 7
 Schelling, Thomas C. 337–8
 schistosomiasis 97
 schoolgirls *see* keeping girls in school
 secondary infection prevention 159, 311
 Sendai virus 313
 Senegal
 alcohol tax 262–3
 HIV incidence/prevalence 13, 114–17
 key indicators 115–16
 problems faced by government (Afrobarometer) 232
 sexual abstinence 68, 255
 sexual abstinence month 4, 71
 sexual behavior, different contexts 283
 sexual health, and CM (contingency management) 55–6
 sexual infections 11, 41–2, 49
 sexual practices, cultural 285
 sexual relations
 frequency 193
 and HIV prevention 11–17, 20, 33, 34–7, 41–2
 risk-taking behavior 56–7
 see also keeping girls in school
 sexually transmitted diseases (STDs)
 and alcohol 243
 HIV 11, 18, 32, 50–2, 63–4, 66–7, 74, 169–70, 238, 300, 339
 prevention basics 67–8
 see also non-sexual HIV transmission
 sexually transmitted infections (STIs) 11, 41–2, 49, 50, 65, 300, 339
 as HIV epidemic drivers 285
 Sierra Leone
 alcohol tax 262–3
 HIV incidence/prevalence 13
 key indicators 115–16
 SIHR (Schooling, Income, and HIV Risk) study 193
 simulated scenarios in ART (anti-retroviral treatment) 135–7
 Smith, Vernon L. 337–8
 Snyder, Richard 288
 social conditions, embodiment of 287–8
 social intervention, and hope 288–90
 social policy interventions 281–90
 Nobel Laureate Economist Expert Panel findings on 339–40
 Somalia, key indicators 115–16
 Somaliland, *Voices of the Poor* project 196
 South Africa
 alcohol tax 262–3
 alcohol taxation 243
 ART program 217
 development indicators 227
 GNI per capita 226–8
 health system capacity 226–8
 HIV epidemic scale 65–6
 HIV incidence/prevalence 12, 13
 HIV testing 195
 HIV/AIDS disease statistics 200
 HIV/AIDS stigma 248–9
 IDU (injecting drug use) intervention 92–5, 96–7
 IMAGE (Intervention with Microfinance for AIDS and Gender Equity) 21, 246, 247
 key indicators 115–16
 life expectancy 226–8
 with/without AIDS 162
 male circumcision 23–5

- Medecins Sans Frontiers project 159
- microfinance schemes 247
- PEPFAR-funded interventions 255
- problematic alcohol use 242
- problems faced by government (Afrobarometer) 232
- TAC (Treatment Action Campaign) 234–5
- unmet need for family planning 165
- voluntary HIV testing and counseling uptake at
 - community level 248
- Spectrum policy models 78–9, 89–90, 93, 96–7, 102, 103–4
- spillover benefits 145
- SROI (Social Return on Investment) 248–9
- SSA *see* sub-Saharan Africa
- stand-alone HIV programs 215
- standard dynamic model of infections 152
 - with interventions 153–4
- statistical life value 189–90
- Stavudine 126, 174
- STDs *see* sexually transmitted diseases
- Stein, Zena 64
- Steinberg, Jonny 234
- Stepping Stones 246, 258–9
- stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242, 248–9, 255, 265
- STIs (sexually transmitted infections) 50, 65, 66–7
- Stover, John 5
- strategies 329
- Strengthening Health Systems 5–6
- stressors 284
- structural drivers metaphor 284–6
- structural interventions 286, 287
- sub-Saharan Africa
 - Abuja Goals Fund (AGF) *see* AGF
 - age-specific survival 29, 30
 - AIDS funding 342
 - AIDS spending and health systems strengthening (HSS) 186–7
 - AIDS vaccine
 - costs 306, 322–3
 - and epidemic future 324
 - ART (anti-retroviral treatment) xix
 - benefits 184
 - coverage 77–8
 - BCC (behavioral change communication) 16
 - behavioral strategies 14–15
 - benefit-cost ratios for ARV 178–82
 - benefits of HIV prevention 306–8
 - blood supply testing 86
 - CCT programs
 - effectiveness 55
 - and keeping girls in school 220–2, 245, 251–2, 254, 258, 293, 294, 343–4
 - Civil Society Panel *see* Civil Society Panel
 - community health workers
 - costs of 196–7
 - deployment 183
 - community mobilization programs 34
 - cost-effectiveness 11, 20, 104
 - cryptococcal antigen (CRAG) test 199–201
 - cryptococcal meningitis 183, 199–201
 - death averted 188–9, 194, 203, 204
 - development indicators 227
 - family planning *see* family planning
 - female sex workers 296–7
 - financial incentives for 5–6
 - gender role perceptions 239, 240, 246–7
 - GNI per capita 75–6
 - HIV incidence in xix, 1, 12, 19, 29, 30, 34, 39–41, 181, 238
 - HIV transmission 238
 - models 79–81, 131–3
 - HIV in women 172–3
 - HIV/AIDS disease statistics 200
 - HIV/AIDS social policy interventions 281–90
 - HIV/AIDS solutions 41–2
 - HTC, home-based 25
 - ICD (infectious and communicable diseases) 188
 - incentivizing adults 296–7
 - income per capita 306
 - increased health spending 188
 - infant infections 198
 - infections and injections 83
 - interventions *see* interventions
 - keeping girls in school *see* keeping girls in school
 - key indicators 115–16
 - labor ward screening 118–19
 - life expectancy 162, 184
 - life-year values 137
 - male circumcision 12, 23–5, 62
 - maternal mortality 197, 198
 - modes of transmission 66–7
 - mother-to-child transmission 74, 107
 - Nobel Laureate Economist Expert Panel findings 337–8
 - OIs (opportunistic infections) 76–7, 78
 - pMTCT benefit-cost ratios 160–1
 - pMTCT options 112–13
 - pMTCT services increase requirements 121–2
 - potential beneficiaries of intervention 39–41
 - potential HIV rates 163
 - pre-exposure chemoprophylaxis 53, 54, 58
 - RethinkHIV* project 11
 - safe blood transfusions 86–8
 - screening tests 161
 - sexual relations and HIV prevention 11–17
 - sexually transmitted HIV 11
 - Strengthening Health Systems 5–6
 - testing and counseling 161
 - treatment cost per person/year 135
 - UNAIDS spending proposal 205
 - universal testing, informing, and counseling 183
 - unmet need for family planning 165
 - women and HIV 172–3
 - substance abuse, as HIV epidemic driver 285
 - Sudan, unmet need for family planning 165
 - supply chain management 323

Swaziland

- alcohol tax 262–3
- ARV requirement 174
- blood transfusion infections 74
- HIV epidemic scale 65–6
- HIV incidence/prevalence 12, 13, 29, 30, 34, 66–7, 114–17
- key indicators 115–16
- life expectancy with/without AIDS 162
- male circumcision 23–5
- resources allocated to 15–17
- sexually transmitted HIV 11
- unmet need for family planning 165
- unsafe medical injections 74

synergies with development sectors 188–9

TAC (Treatment Action Campaign) 234–5

Tanzania

- Abuja target 202
 - alcohol taxation 244, 262–3, 296
 - blood supply testing 86
 - cash incentive programs 57–8
 - CCTs (conditional cash transfers) 245, 296
 - condoms 170
 - cost-effectiveness of HIV prevention 5, 73
 - development indicators 227
 - HIV epidemic scale 65–6
 - HIV incidence/prevalence 13, 283
 - HIV/AIDS stigma 248–9
 - IDU (injecting drug use) intervention 92–5, 96–7
 - intervention studies 170–1
 - key indicators 115–16
 - life expectancy with/without AIDS 162
 - life insurance incentivization 296–7
 - listed HIV epidemic drivers 285
 - Mema kwa Vijana intervention 255
 - problems faced by government (Afrobarometer) 232
 - RESPECT study 193
 - sexually transmitted infections 50
 - unmet need for family planning 165
 - voluntary HIV testing and counseling uptake at
 - community level 248
 - VSL (Value of a Statistical Life) approach 170–1
- Tanzanian AIDS Commission 285
- Tanzanian epidemic 283
- targeting strategy 312
- TASO (AIDS Support Organization) 234–5
- technologies 329
- temporary sexual relationships as HIV epidemic driver 285
- tenofovir 126
- test-and-treat strategy *see* ART
- Thai RV144 vaccine 303, 326
- Thematic Panel Discussion 214
- Togo
- alcohol tax 262–3
 - blood supply testing 86
 - HIV incidence/prevalence 13

- key indicators 115–16
- life expectancy with/without AIDS 162
- topical anti-retrovirals 301
- topical microbicides 238
- transferable social policy interventions 283–4
- transmission susceptibility and income inequality 287
- Treatment 2.0 Initiative 5, 174, 179
- treatment interventions 104–5
- treatment as prevention 166–8, 171–2
- treatment resources vs stated goals 213–14
- treatment unit costs 133–5
- TRIPS (Trade-Related Intellectual Property Rights)
 - agreements 168
- Tshabalala-Msimang, Manto 234
- tuberculosis as investment priority 189

Uganda

- and Abuja Goals Fund (AGF) 207
 - alcohol tax 262–3
 - blood transfusion infections 74
 - CCTs (conditional cash transfers) 245
 - development indicators 227
 - HIV in couples 126
 - HIV epidemic scale 65–6
 - HIV incidence/prevalence 13, 66–7, 81, 324
 - HIV/AIDS stigma 248–9
 - infection age 307
 - injection infections 81
 - interventions, local diagnosis of 289
 - key indicators 115–16
 - life expectancy with/without AIDS 162, 307
 - Masaka intervention 255
 - microfinance schemes 247
 - OIs (opportunistic infections) 76–7, 78
 - PEPFAR-funded interventions 255
 - problems faced by government (Afrobarometer) 232
 - sexually transmitted HIV 11
 - sexually transmitted infections 50
 - TASO (AIDS Support Organization) 234–5
 - unmet need for family planning 165
- UNAIDS 185–6, 188–9, 205, 235–6, 346
- cost of saving life 205–6
 - founding of 61
 - improved investment approach 194–5
 - International Group on Analysis of Trends in HIV Prevalence and Behaviors in Young People in Countries most Affected by HIV (2010) 19
 - investment returns 188
 - and male circumcision 62
 - modes of transmission 66–7
 - program enablers 194–5
- UNAIDS Global Plan 90
- UNAIDS Investment Framework analysis 90
- UNAIDS MOT (Modes of Transmission) model 81
- UNAIDS Strategy (2011–2015) 14–15, 20
- UNAIDS (United Nations Joint Programme on HIV/AIDS) 108–9

- UNDP (Joint United Nations Programme on HIV/AIDS)
 346
 unexamined metaphors 281–6
 UNGASS 189
 unintended pregnancies 197
 unit costs per country 272–3
 United Nations
 General Assembly Political Declaration on HIV/AIDS
 xix, 74
 Security Council Resolution on HIV/AIDS xix
 United Nations High-Level Meeting on AIDS, Thematic
 Panel Discussion 214
 United Nations Non-Communicable Disease Summit
 (2011) 61
 United States, HIV prevalence 153
 universal HIV testing 183, 191–2, 206
 adults 193
 universal precautions intervention 186
- vaccine research and development 7, 299–312, 321–7
 accomplishments to date 300–1
 annual investment in 303–5, 321
 anti-retroviral therapy 330
 benefit-cost analysis 304–9
 of accelerating 309–12
 continued investment 308–9
 benefit-cost ratios 330
 demand creation costs 323
 development history 302–4
 funding sources 300
 infections averted benefits 308
 investment priorities 328–9
 new technologies 328–9
 investments 334
 Nobel Laureate Economist Expert Panel findings on
 337–9
 operational protocols 302
 and productivity levels 311
 prospects 302–4
 R&D 300–4
 research agenda 301–2
 research developments source 313
 secondary infection prevention 311
 and social value 330
 spending 300
 varying average costs 294–5
 Vassall, Anna 6
 VCT (voluntary counseling and testing) *see* HTC
 Vesicular Stomatitis Virus 313
 viral load
 and HIV risk 126, 151
 monitoring 179
Voices of the Poor project 196
 VSL (Value of Statistical Life) approach 170–1
- Watts, Charlotte 6
 Whiteside, Alan 4
- WHO (World Health Organization)
 on alcohol taxation 243
 Options 5, 162–3
 program 162
 women living with HIV, unintended pregnancies 197
 World Bank
 decline in benefit-cost analysis 190
 health funding evaluation 233, 235–6
 results-based funding (RBF) programs 202–3
 structural adjustment lending 231–3
 Voices of the Poor 196
 World Development Report 1993, Investing in Health
 203
 WTP (willingness to pay) 170–1
- ZAC (Zanzibar AIDS Commission) 283
 Zambia
 Abuja target 202
 alcohol tax 262–3
 development indicators 227
 health priority survey 230–1
 health worker shortage 196
 HIV epidemic scale 65–6
 HIV incidence/prevalence 12, 13, 34, 66–7, 196
 key indicators 115–16
 life expectancy with/without AIDS 162
 life insurance incentivization 296–7
 male circumcision 23–5
 OIs (opportunistic infections) 76–7, 78
 problems faced by government (Afrobarometer)
 232
 sexually transmitted HIV 11
 unmet need for family planning 165
 Voices of the Poor project 196
 Zaric, G. S. 295
 ZDV (Zidovudine) program 89, 162–3, 175
 zero uptake
 and benefit-cost ratios 151
 counterfactual 135, 136
 simulation results 139
- Zimbabwe
 alcohol tax 262–3
 development indicators 227
 health priority survey 230–1
 HIV epidemic scale 65–6
 HIV incidence/prevalence 12, 13, 19, 301, 324
 HIV/AIDS stigma 248–9
 key indicators 115–16
 life expectancy with/without AIDS 162
 male circumcision 23–5
 maternal/infant life expectancy 111
 problems faced by government (Afrobarometer)
 232
 unmet need for family planning 165
 voluntary HIV testing and counseling uptake at
 community level 248
 Zuma, Jacob 195